De Wet Reitz Simulation and Economic Analysis Model

De Wet Reitz requires a model to simulate the amount of property conveyance tasks that will be generated at ideal conditions, from the joint venture of a real estate company. The amount of conveyance tasks are determined by a “series” predetermined by De Wet Reitz. These conveyance tasks will generate income; thus resources will be needed to process the conveyance tasks because at present the resources are not optimal and also not sufficient. The simulation of the amount of tasks will be performed by a Monte Carlo simulation that will also display different scenarios. The inputs of the Monte Carlo simulation will be able to be changed as to generate different scenarios. This joint venture project requires investment from other capital sources; therefore a need exists for a model to estimate the break-even point and the capital needed before the break-even point is achieved. In addition there is a need for the optimal amount of resources to optimise the workload and maximise the income relative to the cost. This can be accomplished through a cash flow projection method and calculations completed from the projections. The projections is also required by De Wet Reitz. The model will be built in Java. Java is able to accommodate these simulation needs together with the solutions, for building the simulation model. The model is completed in Java and will accommodate the average income per branch from De Wet Reitz. The model will simulate, optimise and visualise the cash flow of De Wet Reitz and through this method De Wet Reitz will be able to determine whether the scenarios are feasible. The result of the simulation will be measured against De Wet Reitz expectations, if the models’ output shows less than expected management will be able to change inputs and scenarios until the desired effect is achieved, for verification, and what factors should be changed and managed to achieve the desired result. This model may also be edited for future implementation into other De Wet Reitz projects. The model will ultimately simulate the profit and display it as a projection. De Wet Reitz will then be able to identify the number of resources that should be allocated at a specific time, the amount of capital needed for the project and if the project is feasible within a 60 month period.Thesis (B Eng. (Industrial and Systems Engineering))--University of Pretoria, 2012

Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study

Objective: Malignant ovarian germ cell tumors (MOGCT) carry an excellent prognosis, and the treatment aims to achieve results with the least possible treatment-related morbidity. The aim of this study was to assess the outcomes of pediatric patients with MOGCT. Methods: Patients were treated according to their stage: surgery and surveillance for stage I; a modified bleomycin\u2013etoposide\u2013cisplatin (BEP) regimen for stages II (three cycles), III, and IV (three cycles) with surgery on residual disease. Results: Seventy-seven patients were enrolled (median age 11.8 years), 26 with dysgerminoma (Dysg), 13 with immature teratoma and elevated serum alpha-fetoprotein levels (IT+AFP), and 38 with nondysgeminoma (Non-Dysg) staged as follows: 27 stage I, 13 stage II, 32 stage III, 5 stage IV. Among evaluable patients in stage I (5-year event-free survival [EFS] 72.1% [95% CI: 56.4\u201392.1%]; 5-year overall survival [OS] 100%), seven relapsed (three patients with Dysg and four patients with Non-Dysg) and were rescuedwith chemotherapy (plus surgery in three patients). Among the evaluable patients with stages II\u2013IV, 48 (98%) achieved complete remission after chemotherapy \ub1 surgery, one (IT + AFP, stage IV) had progressive disease. In the whole series (median follow-up 80 months), the 5-year OS and EFS were 98.5% (95% CI: 95.6\u2013100%) and 84.5% (95% CI: 76.5\u2013 93.5%). Conclusions:We confirm the excellent outcome for MOGCT. Robust data are lacking on surgical staging, surveillance for Non-Dysg with stage I, the management of IT + AFP, and the most appropriate BEP regimen. As pediatric oncologists,we support the role of surveillance after proper surgical staging providing cases are managed by experts at specialized pediatric centers

GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012

In 2006, under the auspices of The Spanish Research Group for Ovarian Cancer (Spanish initials GEICO), the first “Treatment Guidelines in Ovarian Cancer” were developed and then published in Clinical and Translational Oncology by Poveda Velasco et al. (Clin Transl Oncol 9(5):308–316, 2007). Almost 6 years have elapsed and over this time, we have seen some important developments in the treatment of ovarian cancer. Significant changes were also introduced after the GCIG-sponsored 4th Consensus Conference on Ovarian Cancer by Stuart et al. (Int J Gynecol Cancer 21:750–755, 2011). So we decided to update the treatment guidelines in ovarian cancer and, with this objective, a group of investigators of the GEICO group met in February 2012. This study summarizes the presentations, discussions and evidence that were reviewed during the meeting and during further discussions of the manuscript

Preventive treatments for breast cancer: recent developments

Breast cancer is a burden for western societies, and an increasing one in emerging economies, because of its high incidence and enormous psychological, social, sanitary and economic costs. However, breast cancer is a preventable disease in a significant proportion. Recent developments in the armamentarium of effective drugs for breast cancer prevention (namely exemestane and anastrozole), the new recommendation from the National Institute for Health and Care Excellence to use preventative drugs in women at high risk as well as updated Guidelines from the US Preventive Services Task Force and the American Society of Clinical Oncology should give renewed momentum to the pharmacological prevention of breast cancer. In this article we review recent major developments in the field and examine their ongoing repercussion for breast cancer prevention. As a practical example, the potential impact of preventive measures in Spain is evaluated and a course of practical actions is delineated

Role of Sentinel Lymph Node Biopsy in Cervical Cancer: Pro

Sentinel lymph node biopsy in cervical cancer is used to reduce the morbidity of a full lymph node dissection while improving the pickup rate of metastatic lymph nodes. The higher detection rate achieved can be explained by the following: the identification of the sentinel lymph node in an aberrant location which would not be routinely included in a systematic pelvic lymph node dissection, the sentinel lymph node is completely excised, and the routine use of ultrastaging. The higher detection rate achieved through sentinel lymph node biopsy can identify additional patients who could potentially benefit from adjuvant therapy therefore, in our view the gold standard of lymph node assessment in early stage cervical cancer has shifted and sentinel lymph node biopsy has taken the place of a complete lymphadenectomy.</jats:p